Key Laboratory of Smart Drug Delivery, Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, People's Republic of China.
AAPS J. 2021 Feb 12;23(2):29. doi: 10.1208/s12248-021-00556-2.
Pancreatic cancer is a highly malignant tumor and one of the primary causes of cancer-related death. Because pancreatic cancer is difficult to diagnose in the early course of the disease, most patients present with advanced lesions at the time of diagnosis, and only 20% of patients are eligible for surgery. Consequently, drug treatment has become extremely important. At present, the main treatment regimens for pancreatic cancer are gemcitabine and the FORFIRINOX and MPACT regimens. However, none of these regimens substantially improves the prognosis of patients with pancreatic cancer. Extensive efforts have been dedicated to the study of pancreatic cancer in recent years. With the development and clinical application of biological targeted drugs, the biological targeted treatment of tumors has been widely accepted. Therefore, this article used relevant clinical trial data to summarize the research progress of traditional chemotherapy drugs and biological targeted drugs for the treatment of pancreatic cancer.
胰腺癌是一种高度恶性的肿瘤，也是癌症相关死亡的主要原因之一。由于胰腺癌在疾病早期难以诊断，大多数患者在诊断时已经处于晚期病变，只有 20%的患者适合手术。因此，药物治疗变得非常重要。目前，胰腺癌的主要治疗方案是吉西他滨以及 FORFIRINOX 和 MPACT 方案。然而，这些方案都没有显著改善胰腺癌患者的预后。近年来，人们对胰腺癌进行了广泛的研究。随着生物靶向药物的发展和临床应用，肿瘤的生物靶向治疗已被广泛接受。因此，本文使用相关的临床试验数据总结了传统化疗药物和生物靶向药物治疗胰腺癌的研究进展。
